Publication List
‹ÆÑi2009”Nj

Wataya Y, Naito T, Sato A, Hiramoto A, Kitade Y, Sasaki T, Matsuda A, Fukushima M, Kim HS. Molecular mechanisms of apoptosis induced by 3'-ethynylcytidine. Nucleic Acids Symp Ser (Oxf), 53: 291-2 (2009)

Yonemura Y, Endou Y, Shinbo M, Sasaki T, Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Mizuno M, Miura M, Ikeda M, Ikeda S, Nakajima G, Yonemura J, Yuuba T, Masuda S, Kimura H, Matsuki N. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery. J Surg Oncol, 100 (4): 311-6 (2009)

Kazuno H, Fujioka A, Fukushima M, Wataya Y, Matsuda A, Sasaki T. 1-(3-C-Ethynyl-beta-D-ribo-pentofuranosyl) cytosine (ECyd, TAS-106), a novel potent inhibitor of RNA polymerase, potentiates the cytotoxicity of CDDP in human cancer cells both in vitro and in vivo. Int J Oncol, 34 (5): 1373-80 (2009)

Yamamoto T, Shibata N, Sukeguchi D, Takashima M, Nakamura S, Toru T, Matsunaga N, Hara H, Tanaka M, Obata T, Sasaki T. Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides. Bioorg Med Chem Lett, 19 (14): 3973-6 (2009)

Naito T, Yokogawa T, Takatori S, Goda K, Hiramoto A, Sato A, Kitade Y, Sasaki T, Matsuda A, Fukushima M, Wataya Y, Kim HS. Role of RNase L in apoptosis induced by 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine. Cancer Chemother. Pharmacol, 63 (5): 837-50 (2009)

Suzuki S, Yamamoto E, Tokunaga S. Nakamura S, Tanaka M, Sasaki T, Shibata N. Design and synthesis of thalidomide-deoxyribonucleoside chimeras. Chem Lett, 38 (11): 1046-47 (2009)


ˆîŠ_ K, Ö“¡ —F, Œüˆä ³, ¼ˆä K, Šâ“c ¹, ‰Hª Žõ, –ìŒû r, ’£ŽR ½, ¼”ö Œö, “nç² ~, ²X–Ø ‘ô, ‘å’r —m, ‰Ô‘º ”£, ‘å’| ˜a and ¬o —´ (2009) Ž•‰Èˆã—ÃŒnŠw•”‚Æ–òŠw•”Šw¶‚Ì‹i‰Œó‹µ‚ƎЉï“IƒjƒRƒ`ƒ“ˆË‘¶“x. “ú–{‹Ö‰ŒŠw‰ïŽGŽ 4:78-90.

INDEX